Skip directly to content

Check your knowledge with Toviaz® In Brief

2. Chapple C, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204-12.

http://www.ncbi.nlm.nih.gov/pubmed/17651893

3. Herschorn S, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010;105(1):58-66.

http://www.ncbi.nlm.nih.gov/pubmed/20132103

4. Van Kerrebroeck PEV, et al. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int J Clin Pract. 2012;64(5):584-93.

http://www.ncbi.nlm.nih.gov/pubmed/20201992

The recommended starting dose of Toviaz® is 4 mg once daily. Based upon individual response and tolerance the dose may be increased to 8 mg once daily.
It is recommended to evaluate the efficacy 8 weeks [SMPC]